Pharvaris (PHVS) Projected to Post Quarterly Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is expected to post its quarterly earnings results before the market opens on Wednesday, April 9th. Analysts expect Pharvaris to post earnings of ($0.74) per share for the quarter.

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $14.28 on Monday. The stock has a market cap of $746.70 million, a PE ratio of -5.10 and a beta of -2.84. Pharvaris has a 1 year low of $13.48 and a 1 year high of $25.50. The firm has a fifty day moving average price of $16.31 and a 200-day moving average price of $18.70.

Wall Street Analysts Forecast Growth

Separately, JMP Securities upped their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, January 31st.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.